
An interim phase 1/2 trial update found that DB107-RRV plus DB107-FC could be given in combination with radiation in newly diagnosed high-grade glioma.

An interim phase 1/2 trial update found that DB107-RRV plus DB107-FC could be given in combination with radiation in newly diagnosed high-grade glioma.

Lauren Schaff, MD, discusses safety and overall survival data with L19TNF plus lomustine in recurrent glioblastoma from the phase 2 GLIOSTELLA trial.

Many patients with IDH-mutant glioma continued to receive vorasidenib as directed in the real-world GLIO-ADHERE claims analysis.

Francesco Bruno, MD, PhD, discusses early predictors of vorasidenib response, including volumetric MRI, PET, and seizure control, in IDH-mutant glioma.

Mirdametinib produced stable disease or partial responses in adults and children with plexiform neurofibromas who had received another MEK inhibitor.

Longer follow-up of the phase 3 INDIGO trial showed that vorasidenib lowered seizure rates in IDH-mutant glioma, an effect driven by oligodendroglioma.

Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.

Alexandra M. Miller, MD, discusses whole genome sequencing of cerebrospinal fluid circulating tumor DNA for tracking clonal evolution in high-grade glioma.

Theodore S. Johnson, MD, PhD, discusses immune activation and survival with indoximod plus temozolomide in recurrent ependymoma.

Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.

Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.

Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.

Study findings indicate potential unmet needs for early vorasidenib treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Retrospective data showed vorasidenib displayed strong disease stability in addition to being well tolerated in grade 3 or 4 IDH-mutant glioma.,

B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.

Cassie Kline, MD, MAS, discusses 3-year follow-up data with tovorafenib in patients with pediatric low-grade glioma from FIREFLY-1.

INDIGO TGR analyses showed vorasidenib markedly slowed tumor growth and improved PFS and TTNI vs placebo in IDH1/2-mutant grade 2 glioma.

Christian Grommes, MD, shares results from a phase 2 study evaluating ibrutinib plus rituximab, methotrexate, vincristine, and procarbazine in PSNCL.

Lauren Shaff, MD, contextualizes results from a phase 1 study evaluating copanlisib plus ibrutinib in relapsed/refractory primary and secondary CNS lymphoma.

Lakshmi Nayak, MD, discusses phase 2 efficacy and safety data with tirabrutinib in relapsed/refractory primary and secondary CNS lymphoma.

Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.

Vorasidenib is being integrated in the real-world setting for the treatment of patients with IDH-mutated glioma.

18F-Fluciclovine PET/MRI detected disease progression and ruled out disease in non-progressors among patients with solid tumor brain metastases.

Phase 2 study finds 177Lu-Dotatate safe in advanced intracranial meningioma, with a 6-month PFS rate surpassing historical benchmarks.

Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.

Eflornithine plus lomustine produced superior OS and PFS outcomes vs lomustine in WHO grade 3 IDH-mutated astrocytoma.

Temozolomide plus radiotherapy significantly improved OS vs radiotherapy alone in IDH-mutant low-grade gliomas without codeletions of 1q and 19q.

Macarena de la Fuente, MD, discusses safety data from the phase 1b IDHEAL-4U trial evaluating vorasidenib plus temozolomide in IDH-mutant glioma.

Sylvia C. Kurz, MD, PhD, discusses the ongoing investigation of the SSTR2-targeting agent 177Lu-DOTATATE in advanced intracranial meningioma.

Long-term ReNeu results showed deeper, more durable responses to mirdametinib in NF1-PN with extended treatment in both adults and children.